Brentuximab Vedotin Study in CD30-positive Lymphoma Launched by Takeda
A new study has been initiated to evaluate the safety and usage of brentuximab vedotin in adults with CD30-positive lymphoma.
Indication
Clinical and regulatory intelligence for CD30-positive Lymphoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.